Zegerid Switch Application Expected Before May – Santarus
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough is expected to file a switch application for Santarus' proton pump inhibitor Zegerid with FDA before May, according to the San Diego-based specialty pharmaceutical firm
You may also be interested in...
S-P files NDA for OTC Zegerid
Schering-Plough has filed an Rx-to-OTC switch application with FDA for its proton-pump inhibitor/antacid combination Zegerid (20 mg omeprazole/1100 mg sodium bicarbonate) to treat frequent heartburn, according to a March 11 release. The new drug application was filed under the terms of an October 2006 licensing agreement with San Diego-based Santarus, which discussed the product during a March 3 earnings call (1"The Tan Sheet" March 10, 2008, p. 4). Under standard FDA review, the product could be approved and on the market in early 2009. The immediate-release formula could provide an advantage in the market against Procter & Gamble's OTC PPI Prilosec OTC and private label equivalents...
Zegerid Study Shows Benefits For Immediate-Release PPI/Antacid
Santarus announces positive clinical trial results for its prescription Zegerid proton pump inhibitor/antacid as it pursues an OTC switch application for a lower-dose version of the combination product
Zegerid May Bring Quick Heartburn Relief To Market Under Santarus/S-P deal
Immediate-release delivery will give Santarus' proton pump inhibitor Zegerid (omeprazole/sodium bicarbonate) an edge against Prilosec OTC in the heartburn market if the firm can pull off a planned Rx-to OTC switch